A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

This study is testing a combination of a new immunotherapy drug called carbognilumab together with standard chemotherapy as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) that carries a mutation in a gene called STK11. STK11-mutated lung cancers typically don't respond well to standard immunotherapy, and researchers are exploring whether this combination can overcome that resistance. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with advanced or recurrent NSCLC confirmed by biopsy or cytology - Your tumor has an STK11 gene mutation detected by genetic testing (NGS) - Your tumor does not have other treatable driver mutations (such as EGFR, ALK, ROS1, etc.) - You have not yet received systemic (whole-body) cancer treatment for your advanced disease, OR you completed adjuvant/neoadjuvant treatment more than 12 months ago - You have at least one measurable tumor lesion on imaging **You may NOT be eligible if:** - Your tumor has other driver mutations that have approved targeted therapies - You have already received immunotherapy or systemic cancer therapy for advanced disease - You have had recent anticancer treatment with less than a 4-week gap - You have unresolved significant side effects from previous treatments Talk to your doctor to see if this trial is right for you.